Please select the option that best describes you:
Topics:
Rheumatology • Rheumatoid Arthritis • General Rheumatology • Infectious Disease • General Infectious Disease • Orthopedics
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
Pt has active RA despite hydroxychloroquine with synovitis in multiple joints of hands and wrists.